Scioderm Inc.
Treating skin lesions and blistering in rare disease
This article was originally published in Start Up
Executive Summary
Scioderm Inc. thinks it can break the long string of failures in wound healing with an experimental therapy called Zorblisa, which it is developing as a topical treatment for epidermolysis bullosa, a rare connective tissue disease that causes skin to tear easily. The FDA has designated it a breakthrough therapy; if Phase III data look good, Scioderm could bring Zorblisa to market in the US and Europe by the end of 2016.
You may also be interested in...
Skin Is In With Biomedical Investors
Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.